Genmab マネジメント

マネジメント基準チェック /34

Genmabの CEO はJan G.J. de Winkelで、 Jun2010年に任命され、の在任期間は 15.75年です。の年間総報酬は$ 10.70Mで、 14%給与と86%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.07%を直接所有しており、その価値は$ 183.86M 。経営陣と取締役会の平均在任期間はそれぞれ6年と8年です。

主要情報

Jan G.J. de Winkel

最高経営責任者

US$10.7m

報酬総額

CEO給与比率	14.02%
CEO在任期間	15.8yrs
CEOの所有権	1.1%
経営陣の平均在職期間	6yrs
取締役会の平均在任期間	8yrs

経営陣の近況

Recent updates

CEO報酬分析

Genmab の収益と比較して、Jan G.J. de Winkel の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Dec 31 2025	US$11m	US$2m	US$963m
Sep 30 2025	n/a	n/a	US$2b
Jun 30 2025	n/a	n/a	US$1b
Mar 31 2025	n/a	n/a	US$1b
Dec 31 2024	US$8m	US$1m	US$1b
Sep 30 2024	n/a	n/a	US$702m
Jun 30 2024	n/a	n/a	US$798m
Mar 31 2024	n/a	n/a	US$791m
Jan 01 2024	n/a	n/a	US$631m
Sep 30 2023	n/a	n/a	US$590m
Jun 30 2023	n/a	n/a	US$680m
Mar 31 2023	n/a	n/a	US$757m
Dec 31 2022	US$6m	US$1m	US$785m
Sep 30 2022	n/a	n/a	US$745m
Jun 30 2022	n/a	n/a	US$558m
Mar 31 2022	n/a	n/a	US$354m
Dec 31 2021	US$6m	US$1m	US$452m
Sep 30 2021	n/a	n/a	US$448m
Jun 30 2021	n/a	n/a	US$401m
Mar 31 2021	n/a	n/a	US$880m
Dec 31 2020	US$6m	US$1m	US$781m
Sep 30 2020	n/a	n/a	US$889m
Jun 30 2020	n/a	n/a	US$853m
Mar 31 2020	n/a	n/a	US$349m
Dec 31 2019	US$5m	US$1m	US$325m

報酬と市場: Jan G.J.の総報酬 ($USD 10.70M ) は、 US市場 ($USD 13.27M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Jan G.J.の報酬は 20% 以上増加しましたが、会社の収益は過去 1 年間で 20% 以上減少しました。

CEO

Jan G.J. de Winkel (64 yo)

15.8yrs

在職期間

US$10,700,000

報酬

Dr. Jan G.J. van de Winkel, Ph.D. was Independent Director of HOOKIPA Pharma Inc. from 2023 until August 30, 2024 and served as Chairman of the Board since 2024 August 30, 2024. Dr. Winkel served as a Memb...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jan G.J. de Winkel	Co-Founder	15.8yrs	US$10.70m	1.07% $ 183.9m
Anthony Pagano	Executive VP & CFO	6yrs	US$4.70m	0.0096% $ 1.6m
Rayne Waller	Executive VP & Chief Technical Operations Officer	1.6yrs	US$2.70m	データなし
Gregory David Mueller	Executive VP	less than a year	US$1.80m	データなし
Christopher Cozic	Executive VP & Chief People Officer	8.3yrs	US$3.40m	データなし
Martine van Vugt	Executive VP & Chief Strategy Officer	12.2yrs	US$2.40m	データなし
Martin Schultz	Senior Director	no data	US$300.00k	0.0011% $ 185.5k
Judith Klimovsky	Executive VP & Chief Development Officer	9.1yrs	US$5.40m	0.018% $ 3.0m
Tahamtan Ahmadi	Executive VP	5yrs	US$5.20m	0.0079% $ 1.4m
Mijke Zachariasse	VP, Head of Antibody Research Materials & Director	no data	US$300.00k	0.0013% $ 219.9k
Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	no data	US$100.00k	0.00013% $ 22.3k
Brad Bailey	Executive VP & Chief Commercial Officer	1.6yrs	US$2.10m	データなし

6.0yrs

平均在職期間

53yo

平均年齢

経験豊富な経営陣: GMABの経営陣は経験豊富で経験豊富です（平均在職期間は6年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Martin Schultz	Senior Director	4.2yrs	US$300.00k	0.0011% $ 185.5k
Mijke Zachariasse	VP, Head of Antibody Research Materials & Director	7yrs	US$300.00k	0.0013% $ 219.9k
Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	4.2yrs	US$100.00k	0.00013% $ 22.3k
Michael Kavanagh	Senior Director	1.2yrs	US$200.00k	0.00036% $ 61.8k
Anders Pedersen	Non-Independent Director	22.3yrs	US$400.00k	0.013% $ 2.2m
Elizabeth O'Farrell	Independent Director	4yrs	US$400.00k	0.0031% $ 525.7k
Deirdre Connelly	Independent Chairman of the Board	9yrs	US$600.00k	0.011% $ 1.8m
Rolf Hoffmann	Independent Director	9yrs	US$400.00k	0.0061% $ 1.1m
Pernille Erenbjerg	Independent Deputy Chairman	11.2yrs	US$400.00k	0.0089% $ 1.5m
Paolo Paoletti	Independent Director	11.2yrs	US$300.00k	0.0041% $ 699.2k

8.0yrs

平均在職期間

59.5yo

平均年齢

経験豊富なボード: GMABの取締役会は経験豊富であると考えられます ( 8年の平均在任期間)。

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/03/04 02:44
終値	2026/03/04 00:00
収益	2025/12/31
年間収益	2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成する分析モデルの詳細は当社の Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや YouTubeのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Genmab A/S 16 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。36

アナリスト	機関
Emily Field	Barclays
James Gordon	Barclays
Xue Chen	Barclays

Genmab マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Genmab A/S, Annual General Meeting, Mar 19, 2026

Genmab Announces Changes to Its Executive Committee

Genmab A/S, Annual General Meeting, Mar 12, 2025

Genmab A/S Announces Executive Changes

Genmab A/S Announces Executive Changes

Genmab A/S, Annual General Meeting, Mar 13, 2024

Recent updates

Genmab A/S, Annual General Meeting, Mar 19, 2026

Genmab Provides Earnings Guidance for the Full Year 2026

Genmab: Darzalex Growth Fuels Rally, Upside Is Tight

Genmab A/S Announces Topline Results for Epcoritamab (DuoBody CD3xCD20) from Phase 3 EPCORE DLBCL-1 Trial in Patients with Relapsed Refractory Diffuse Large B-Cell Lymphoma

Genmab A/S to Discontinue Further Clinical Development of Acasunlimab Following A Portfolio Review

Genmab A/S (CPSE:GMAB) completed the acquisition of Merus N.V. (NasdaqGM:MRUS) in a tender offer transaction.

Genmab A/S Announces EPKINLY (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

Genmab A/S to Report First Half, 2026 Results on Aug 06, 2026

Genmab Provides Earnings Guidance for the Full Year 2025

Genmab A/S Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®?) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

Genmab Reportedly in Advanced Talks to Buy Merus

Genmab A/S Announces Updated Results from Phase 2 Epcore®? Nhl-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (Dlbcl)

Genmab A/S Raises Earnings Guidance for the Year 2025

Genmab Announces Changes to Its Executive Committee

Genmab A/S Announces Investigational Rinatabart Sesutecan (Rina-S) Demonstrates Encouraging Anti-Tumor Activity Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL-01 Trial

Genmab A/S to Present New and Updated Results from Its Robust Epcoritamab (Epkinly®) Development Program At the 2025 European Hematology Association (Eha) Congress

Genmab A/S to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed Refractory Follicular Lymphoma

Genmab's Outlook Beyond Darzalex's Patent Cliff

Genmab A/S Announces Japan Ministry of Health, Labour and Welfare Approves TIVDAK for the Treatment of Advanced or Recurrent Cervical Cancer

Genmab A/S Updates Data from Cohort B1 of the Phase 1/2 RAINFOL-01 Study of Rina-S

Genmab: GEN3014's Demise And Implications For The HexaBody Platform

Genmab A/S, Annual General Meeting, Mar 12, 2025

Genmab A/S Provides Revenue Guidance for 2025

Genmab A/S Announces New Results from the Phase 1b/2 EPCORE NHL-2 Trial

Genmab Is Too Attractive To Ignore

Genmab: Looking To Manage My Position Around Q3 Earnings

Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate

Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Genmab A/S Takes Full Control of Acasunlimab Development Program

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Genmab: A Complicated Tale

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab Acquires A Missing Piece For Its Pipeline

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab: Recent Updates Support The Growth Narrative

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade)

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Genmab: 3 Trends To Track For A Strong 2024 And Beyond

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Revises Earnings Guidance for the Year 2023

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Genmab reports Q3 worldwide sales of $2.05B for Darzalex

Genmab improves FY 2022 guidance

Genmab reports Q2 worldwide net sales of DARZALEX $1.99B

Genmab: A Royalty Powerhouse With A Strong Pipeline

CEO報酬分析

CEO

マネジメント基準チェック /34